Drug Profile
Research programme: anticancer therapeutics - Tri-Institutional Therapeutics Discovery Institute/Takeda
Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Takeda; Tri-Institutional Therapeutics Discovery Institute
- Developer Takeda
- Class Antibodies; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Cancer in USA
- 16 Jun 2016 Takeda and Tri-Institutional Therapeutics Discovery Institute expand their collaboration to co-develop antibody based therapeutics in USA for Cancer and Undefined indications
- 01 Oct 2013 Takeda and Tri-Institutional Therapeutics Discovery Institute agree to co-develop small molecule therapeutics in USA for Cancer and Undefined indications